Breaking News, Financial News

Financial Report: Lilly 2Q

Product sales were up 2% to $5.1 billion, while alliance revenue rose 54% to $179.5 million, primarily due to Erbitux revenues through the ImClone acquisition.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Lilly 2Q 2Q Revenues: $5.3 billion (+3%) 2Q Earnings: $1.2 billion (+21%) YTD Revenues: $10.3 billion (+2%) YTD Earnings: $2.5 billion (+28%) Comments: Product sales were up 2% to $5.1 billion, while alliance revenue rose 54% to $179.5 million, primarily due to Erbitux revenues through the ImClone acquisition. Zyprexa sales were $1.2 billion (-3%). Cymbalta sales were $744.4 million(+14%). Humalog sales were $477.5 million (+9%). Cialis sales were flat at $363.6 million. Gemzar sa...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters